Volume 24, Number 10 (Jan 2017) | JSSU 2017, 24(10): 780-789 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Haghiralsadat F, Amoabediny G, Sheikhha M, Mohammad nezhad J, Naderinezhad S, Malaei-Balasi Z et al . New Approach for the Synthesis, Entrapment of Hydrophilic Drugs and Evaluation of Physico-Chemical Characteristics of PH-sensitive Nano-Liposome: Improving Therapeutic Efficacy of Doxorubicin in Order to Treatment Bone Tumor and Reducing the Side Effects of Doxorubicin. JSSU. 2017; 24 (10) :780-789
URL: http://jssu.ssu.ac.ir/article-1-3625-en.html

Abstract:   (950 Views)

Introduction: Cancer is one of the most harmful disease throughout the world. Doxorubicin is an anti-cancer agent, used in the treatment of various types of the cancer such as bone cancer. There are several adverse effects related to clinical usage of Doxorubicin for long time. The present study aimed to investigate the reducing side effects and enhancing the therapeutic effect by liposomal carrier.

Methods: Liposomes containing DPPG and cholesterol with the molar ratio of 70:30 with the Doxorubicin were synthesized by pH- gradient method. The average diameter of nanoparticles and surface charge was determined by Zeta-Sizer instrument. The amount of drug loaded and drug-released was determined using dialysis. The surface morphology and internal lamella was evaluated by TEM and SEM.

Results: The average size of liposomal Doxorubicin obtained using Zeta-Sizer was 126 nm. The encapsulation efficacy of liposomal Doxorubicin was 89%. The total amount of drug release during 48 hours in acidic medium studied by dialysis technique was 46%.

Conclusion: In this study, investigation of loading Doxorubicin into nano-liposome with the slow- released kinetic was carried out to improve the solubility and bioavailability of Doxorubicin in order to delivery to osteosarcoma cell line.

Full-Text [PDF 1534 kb]   (449 Downloads)    
Type of Study: Original article | Subject: other
Received: 2016/02/20 | Accepted: 2016/09/24 | Published: 2017/01/21

1. 1- Guo J, Bourre L, Soden DM, O'Sullivan GC, O'Driscoll C. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnol. Adv 2011; 29(4): 402-17.
2. 2- Nussbaum RL, McInnes RR, Willard HF. Willard, Thompson and Thompson genetics in medicine, Elsevier Health Sciences, 2004.
3. 3- Martin JW, Squire JA, Zielenska M. The genetics of osteosarcoma, Sarcoma 2012.
4. 4- Wu SY, McMillan NA. Lipidic systems for in vivo siRNA delivery. AAPS J 2009; 11(4): 639-52.
5. 5- Barenholz Y, Gabizon A. Gabizon, Liposome/doxorubicin composition and method, (1990).
6. 6- Riaz M. Liposomes preparation methods. Pak J Pharm Sci 1996; 9(1): 65-77.
7. 7- Sun R, Liu Y, Li SY, Shen S, Du XJ, Xu CF, et al. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials 2015; 37: 405-14.
8. 8- Kennedy LC, Bickford LR, Lewinski NA, Coughlin AJ, Hu Y, Day ES, et al. A New Era for Cancer Treatment: Gold‐Nanoparticle‐Mediated Thermal Therapies. Small 2011; 7(2): 169-83.
9. 9- Ho JA, Lin YC. Device for preparation of liposomes and method thereof. U.S. Patent 8,932,498 (2015).
10. 10- Koo OM, Rubinstein I, Onyuksel H. Onyuksel, Role of nanotechnology in targeted drug delivery and imaging: a concise review, Nanomedicine Nanotechnology. Biol. Med 2005; 1(3): 193-212.
11. 11- Markley KS. Soybeans and soybean products. (1951).
12. 12- Haghiralsadat F, Amoabediny G, Sheikhha MH, Forouzanfar T, Helder MN, Zandieh-doulabi B. A novel approach on drug delivery: Investigation of new nano-formulation of liposomal doxorubicin and biological evaluation of entrapped doxorubicin on various osteosarcomas cell lines. Cell J 2016.
13. 13- Costantino L, Boraschi D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov Today. 17 (2012) 367–378.
14. 14- Weissig V. Liposomes: Methods and Protocols, Volume 1: Pharmaceutical Nanocarriers./Mozafari MR. Ch. 2: Nanoliposomes: Preparation and Analysis. Springer 2010; 12: 29-50.
15. 15- Torchilin VP. Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov 2005; 4(2): 145-60.
16. 16- Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19(5): 1444-454.
17. 17- Eliaz RE, Nir S, Marty C, Szoka FC. Determination and modeling of kinetics of cancer cell killing by doxorubicin and doxorubicin encapsulated in targeted liposomes. Cancer Res 2004; 64(2): 711-18.
18. 18- Tan ML, Friedhuber AM, Dunstan DE, Choong PF, Dass CR. Dass, The performance of doxorubicin encapsulated in chitosan–dextran sulphate microparticles in an osteosarcoma model. Biomaterials 2010; 31(3): 541-51.

Add your comments about this article : Your username or email:
Write the security code in the box

Send email to the article author

© 2015 All Rights Reserved | SSU_Journals

Designed & Developed by : Yektaweb